The latest price target for Centessa Pharmaceuticals (NASDAQ:CNTA) was reported by Wells Fargo on April 20, 2026. The analyst firm set a price target for $42.00 expecting CNTA to rise to within 12 months (a possible 5.61% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Centessa Pharmaceuticals (NASDAQ:CNTA) was provided by Wells Fargo, and Centessa Pharmaceuticals downgraded their equal-weight rating.

The last upgrade for Centessa Pharmaceuticals PLC happened on September 19, 2024 when Morgan Stanley raised their price target to $26. Morgan Stanley previously had an equal-weight for Centessa Pharmaceuticals PLC.

The last downgrade for Centessa Pharmaceuticals PLC happened on April 20, 2026 when Wells Fargo changed their price target from $35 to $42 for Centessa Pharmaceuticals PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on April 20, 2026 so you should expect the next rating to be made available sometime around April 20, 2027.

While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a downgraded with a price target of $35.00 to $42.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $39.77, which is within the analyst’s predicted range.